Therapy of pericarditis with colchicine, interleukin-1 antagonists, immunosuppressants
https://doi.org/10.30629/0023-2149-2023-101-1-6-17
Abstract
Eight years have passed since the update of the European Guidelines for the management of pericarditis, almost 3 years of which the pandemic of the new coronavirus has been continuing. COVID-19 has changed the structure and the course of all cardiac diseases. At present there is no doubt that the dominant cause of pericarditis is the new coronavirus SARS-CоV-2. However, such non-infectious causes as systemic inflammatory diseases, paraneoplastic and postpericardiotomy syndromes that require a differentiated therapeutic strategy, remain relevant. This part of the systematic review addresses the treatment of incessant, recurrent, and chronic viral/idiopathic pericarditis. Particular attention is paid to publications on the effectiveness of the therapy with colchicine and interleukin-1 antagonists. The review of the medical resources such as PubMed, Google Scholar, UpToDate (publications from 01.1990 to 10.2022) was conducted, the issues of differentiated pericarditis therapy with various anti-inflammatory drugs were studied thoroughly.
About the Authors
Z. N. Sukmarova
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
Sukmarova Zulfiya N.
115522, Moscow
V. B. Simonenko
Branch Military Medical Academy named after S.M. Kirov in Moscow of the Ministry of Defense of Russia
Russian Federation
Russian Federation
Simonenko Vladimir B.
107392, Moscow
E. L. Nasonov
V.A. Nasonova Research Institute of Rheumatology; I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)
Russian Federation
Russian Federation
Nasonov Evgeny L.
107392, Moscow
119991 Moscow
References
1. Adler Y., Char ron P., Imazio M., Badano L., Barón-Esquivias G., Bogaert J., Brucato A., Gueret P., Klingel K., Lionis C., Maisch B., Mayosi B., Pavie A., Ristic A.D., Sabaté Tenas M., Seferovic P., Swedberg K., Tomkowski W.; ESC Scientifi c Document Group. 2015 ESC Guidelines for the diagnosis and management of pericardial diseases: The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC)Endorsed by: The European Association for Cardio-Thoracic Surgery (EACTS). Eur. Heart J. 2015;36(42):2921–2964. DOI: 10.1093/eurheartj/ehv318
2. Imazio M., Brucato A., Derosa F.G., Lestuzzi C., Bombana E., Scipione F., Leuzzi S., Cecchi E., Trinchero R., Adler Y. Aetiological diagnosis in acute and recurrent pericarditis: when and how. J. Cardiovasc. Med. (Hagerstown). 2009;10(3):217–30. DOI: 10.2459/JCM.0b013e328322f9b1
3. Imazio M., Brucato A., Cemin R., Ferrua S., Maggiolini S., Beqaraj F., Demarie D., Forno D., Ferro S., Maestroni S., Belli R., Trinchero R., Spodick D.H., Adler Y.; ICAP Investigators. A randomized trial of colchicine for acute pericarditis. N. Engl. J. Med. 2013;369:1522–1528. DOI: 10.1056/NEJMoa1208536
4. Cremer P.C., Kumar A., Kontzias A., Tan C.D., Rodriguez E.R., Imazio M., Klein A.L. Complicated Pericarditis: Understanding Risk Factors and Pathophysiology to Inform Imaging and Treatment. J. Am. Coll. Cardiol. 2016;68(21):2311–2328. DOI: 10.1016/j.jacc.2016.07.785.
5. Brucato A., Brambilla G., Moreo A., Alberti A., Munforti C., Ghirardello A., Doria A., Shinar Y., Livneh A., Adler Y., Shoenfeld Y., Mauri F., Palmieri G., Spodick D.H. Long-term outcomes in diffi - cult-to-treat patients with recurrent pericarditis. Am. J. Cardiol. 2006;98(2):267–271. DOI: 10.1016/j.amjcard.2006.01.086
6. Lin D., Laliberté F., Majeski C., Magestro M., Lejeune D., Duh M.S., Lim-Watson M., Paolini J.F. Disease and economic burden associated with recurrent pericarditis in a privately insured United States population. Adv. Ther. 2021;38(10):5127–5143. DOI: 10.1007/s12325-021-01868-7
7. Lutschinger L.L., Rigopoulos A.G., Schlattmann P., Matiakis M., Sedding D., Schulze P.C., Noutsias M. Meta-analysis for the value of colchicine for the therapy of pericarditis and of postpericardiotomy syndrome. BMC Cardiovasc. Disord. 2019;19(1):207. DOI: 10.1186/s12872-019-1190-4
8. Sukmarova Z.N., Simonenko V.B., Nasonov E.L. Treatment of patients with pericarditis with anti-infl ammatory drugs. Klinicheskaya meditsina. 2022;100(11–12):509–519. (In Russian). DOI: http://dx.doi.org/10.30629/0023-2149-2022-100-11-12
9. Imazio M., Brucato A., Lazaros G., Andreis A., Scarsi M., Klein A., De Ferrari G.M., Adler Y. Anti-infl ammatory therapies for pericardial diseases in the COVID-19 pandemic: safety and potentiality. J. Cardiovasc. Med. (Hagerstown). 2020;21(9):625–629. DOI: 10.2459/JCM.0000000000001059
10. Vecchié A., Del Buono M.G., Chiabrando G.J., Dentali F., Abbate A., Bonaventura A. Interleukin-1 and the NLRP3 Infl ammasome in Pericardial Disease. Curr. Cardiol. Rep. 2021;23(11):157. DOI: 10.1007/s11886-021-01589-x
11. Toldo S., Abbate A. The NLRP3 infl ammasome in acute myocardial infarction. Nat. Rev. Cardiol. 2018;15:203–14. DOI: 10.1038/nrcardio.2017.161
12. Bonaventura A., Vecchie A., Mauro A.G., Brucato A.L., Imazio M., Abbate A. An update on the pathophysiology of acute and recurrent pericarditis. Panminerva Med. 2020. DOI: 10.23736/S0031-0808.20.04205-6
13. Mauro A.G., Bonaventura A., Vecchié A., Mezzaroma E., Carbone S., Narayan P., Potere N., Cannatà A., Paolini J.F., Bussani R., Montecucco F., Sinagra G., Van Tassel B.W., Abbate A., Toldo S. The Role of NLRP3 Infl ammasome in Pericarditis: Potential for Therapeutic Approaches. JACC Basic Transl. Sci. 2021;6(2):137– 150. DOI: 10.1016/j.jacbts.2020.11.016
14. Deftereos S.G., Siasos G., Giannopoulos G., Vrachatis D.A., Angelidis C., Giotaki S.G., Gargalianos P., Giamarellou H., Gogos C., Daikos G., Lazanas M., Lagiou P., Saroglou G., Sipsas N., Tsiodras S., Chatzigeorgiou D., Moussas N., Kotanidou A., Koulouris N., Oikonomou E., Kaoukis A., Kossyvakis C., Raisakis K., Fountoulaki K., Comis M., Tsiachris D., Sarri E., Theodorakis A., Martinez-Dolz L., Sanz-Sánchez J., Reimers B., Stefanini G.G., Cleman M., Filippou D., Olympios C.D., Pyrgakis V.N., Goudevenos J., Hahalis G., Kolettis T.M., Iliodromitis E., Tousoulis D., Stefanadis C. The Greek study in the eff ects of colchicine in COVID-19 complications prevention (GRECCO-19 study): Rationale and study design. Hellenic J. Cardiol. 2020;61(1):42–45. DOI: 10.1016/j.hjc.2020.03.002
15. Angelidis C., Kotsialou Z., Kossyvakis C., Vrettou A.R., Zacharoulis A., Kolokathis F., Kekeris V., Giannopoulos G. Colchicine Pharmacokinetics and Mechanism of Action. Curr. Pharm. Des. 2018;24(6):659–663. DOI: 10.2174/1381612824666180123110042
16. Imazio M., Bobbio M., Cecchi E., Demarie D., Demichelis B., Pomari F., Moratti M., Gaschino G., Giammaria M., Ghisio A., Belli R., Trinchero R. Colchicine in addition to conventional therapy for acute pericarditis: results of the COlchicine for acute PEricarditis (COPE) trial. Circulation. 2005;112(13):2012–6. DOI: 10.1161/CIRCULATIONAHA.105.542738
17. Sambola A., Roca Luque I., Mercé J., Alguersuari J., Francisco-Pascual J., García-Dorado D., Sagristà-Sauleda J. Colchicine Administered in the First Episode of Acute Idiopathic Pericarditis: A Randomized Multicenter Open-label Study. Rev. Esp. Cardiol. (Engl Ed). 2019;72(9):709–716. English, Spanish. DOI: 10.1016/j.rec.2018.11.016
18. Imazio M. Why Colchicine Should Continue To Be The First Line Therapy For Acute And Recurrent Pericarditis. Rev. Esp. Cardiol. (Engl Ed) 2019; 72:705. DOI: 10.1016/j.rec.2019.03.009
19. Imazio M., Bobbio M., Cecchi E., Demarie D., Pomari F., Moratti M., Ghisio A., Belli R., Trinchero R. Colchicine as fi rst-choice therapy for recurrent pericarditis: results of the CORE (COlchicine for REcurrent pericarditis) trial. Arch. Intern. Med. 2005;165(17):1987– 91. DOI: 10.1001/archinte.165.17.1987
20. Imazio M., Brucato A., Cemin R., Ferrua S., Belli R., Maestroni S., Trinchero R., Spodick D.H., Adler Y.; CORP (COlchicine for Recurrent Pericarditis) Investigators. Colchicine for recurrent pericarditis (CORP): a randomized trial. Ann. Intern. Med. 2011;155:409–414. DOI: 10.7326/0003-4819-155-7-201110040-00359
21. Imazio M., Belli R., Brucato A., Cemin R., Ferrua S., Beqaraj F., Demarie D., Ferro S., Forno D., Maestroni S., Cumetti D., Varbella F., Trinchero R., Spodick D.H., Adler Y. Effi cacy and safety of colchicine for treatment of multiple recurrences of pericarditis (CORP-2): a multicentre, double-blind, placebo-controlled, randomised trial. Lancet. 2014;383:2232–2237
22. Imazio M., Brucato A., Forno D., Ferro S., Belli R., Trinchero R., Adler Y. Effi cacy and safety of colchicine for pericarditis prevention. Systematic review and meta-analysis. Heart. 2012;98(14):1078–82. DOI: 10.1136/heartjnl-2011-301306
23. Alabed S., Cabello J.B., Irving G.J., Qintar M., Burls A. Colchicine for pericarditis. Cochrane Database Syst. Rev. 2014;(8):CD010652. DOI: 10.1002/14651858.CD010652.pub2
24. Imazio M., Brucato A., Belli R., Forno D., Ferro S., Trinchero R., Adler Y. Colchicine for the prevention of pericarditis: what we know and what we do not know in 2014 — systematic review and metaanaly sis. J. Cardiovasc. Med. (Hagerstown). 2014;15(12):840–6. DOI: 10.2459/JCM.0000000000000103
25. Artom G., Koren-Morag N., Spodick D.H., Brucato A., Guindo J., Bayes-de-Luna A., Brambilla G., Finkelstein Y., Granel B., Bayes-Genis A., Schwammenthal E., Adler Y. Pretreatment with corticosteroids attenuates the effi cacy of colchicine in preventing recurrent pericarditis: a multi-centre all-case analysis. Eur. Heart J. 2005;26:723. DOI: 10.1093/eurheartj/ehi197
26. Richter M., Boldescu V., Graf D., Streicher F., Dimoglo A., Bartenschlager R., Klein C.D. Synthesis, Biological Evaluation, and Molecular Docking of Combretastatin and Colchicine Derivatives and their hCE1-Activated Prodrugs as Antiviral Agents. Chem. Med. Chem. 2019;14(4):469–483. DOI: 10.1002/cmdc.201800641
27. Biswas K., Das Sarma J. Eff ect of microtubule disruption on neuronal spread and replication of demyelinating and nondemyelinating strains of mouse hepatitis virus in vitro. J. Virol. 2014;88:3043–3079. DOI: 10.1128/JVI.02545-13
28. Lu N., Yang Y., Liu H., Ding X., Ou Y., Xia J., Du Y. Inhibition of respiratory syncytial virus replication and suppression of RSV-induced airway infl ammation in neonatal rats by colchicine. 3 Biotech. 2019;9(11):392. DOI: 10.1007/s13205-019-1917-z
29. Worachartcheewan A., Songtawee N., Siriwong S., Prachayasittikul S., Nantasenamat C., Prachayasittikul V. Rational design of colchicine derivatives as anti-HIV agents via QSAR and molecular docking. Med. Chem. 2019;15:328–340. DOI: 10.2174/1573406414666180924163756
30. Milewska A., Nowak P., Owczarek K., Szczepanski A., Zarebski M., Hoang A., Berniak K., Wojarski J., Zeglen S., Baster Z., Rajfur Z., Pyrc K. Entry of Human Coronavirus NL63 into the Cell. J. Virol. 2018;92(3):e01933–17. DOI: 10.1128/JVI.01933-17
31. Lopes M.I., Bonjorno L.P., Giannini M.C., Amaral N.B., Menezes P.I., Dib S.M., Gigante S.L., Benatti M.N., Rezek U.C., Emrich-Filho L.L., Sousa B.A.A., Almeida S .C .L., Luppino Assad R., Veras F.P., Schneider A., Rodrigues T.S., Leiria L .O .S., Cunha L.D., Alves-Filho J.C., Cunha T.M., Arruda E., Miranda C.H., Pazin-Filho A., Auxiliadora-Martins M., Borges M.C., Fonseca B.A.L., Bollela V.R., Del-Ben C.M., Cunha F.Q., Zamboni D.S., Santana R.C., Vilar F.C., Louzada-Junior P., Oliveira R.D.R. Benefi cial eff ects of colchicine for moderate to severe COVID-19: a randomised, double-blinded, placebo-controlled clinical trial. RMD Open. 2021;7(1):e001455. DOI: 10.1136/rmdopen-2020-001455
32. Deftereos S.G., Giannopoulos G., Vrachatis D.A., Siasos G.D., Giotaki S.G., Gargalianos P., Metallidis S., Sianos G., Baltagiannis S., Panagopoulos P., Dolianitis K., Randou E., Syrigos K., Kotanidou A., Koulouris N.G., Milionis H., Sipsas N., Gogos C., Tsoukalas G., Olympios C.D., Tsagalou E., Migdalis I., Gerakari S., Angelidis C., Alexopoulos D., Davlouros P., Hahalis G., Kanonidis I., Katritsis D., Kolettis T., Manolis A.S., Michalis L., Naka K.K., Pyrgakis V.N., Toutouzas K.P., Triposkiadis F., Tsioufi s K., Vavouranakis E., Martinèz-Dolz L., Reimers B., Stefanini G.G., Cleman M., Goudevenos J., Tsiodras S., Tousoulis D., Iliodromitis E., Mehran R., Dangas G., Stefanadis C.; GRECCO-19 investigators. Eff ect of Colchicine vs Standard Care on Cardiac and Infl ammatory Biomarkers and Clinical Outcomes in Patients Hospitalized With Coronavirus Disease 2019: The GRECCO-19 Randomized Clinical Trial. JAMA Netw. Open. 2020;3(6):e2013136. DOI: 10.1001/jamanetworkopen.2020.13136
33. Tardif J-C, Bouabdallaoui N, L’Allier PL, et al. Effi cacy of Colchicine in Non-Hospitalized Patients with COVID-19. MedRxiv. 2021. DOI: 10.1101/2021.01.26.21250494
34. Horby P.W., Campbell M., Spata E. et al. for the RECOVERY Collaborative Group. Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet Respir. Med. 2021;9(12):1419–1426. DOI: 10.1016/S2213-2600(21)00435-5
35. Mikolajewska A., Fischer A.L., Piechotta V., Mueller A., Metzendorf M.I., Becker M., Dorando E., Pacheco R.L., Martimbianco ALC., Riera R., Skoetz N., Stegemann M. Colchicine for the treatment of COVID-19. Cochrane Database of Systematic Reviews. 2021;10(10):CD015045. DOI: 10.1002/14651858.CD015045
36. Chiu L, Chow R, Chiu N, et al. Colchicine use in patients with COVID-19: a systematic review and meta-analysis. MedRxiv. 2021. DOI: 10.1101/2021.02.02.21250960
37. Diaz R., Orlandini A., Castellana N., Caccavo A., Corral P., Corral G., Chacón C., Lamelas P., Botto F., Díaz M.L., Domínguez J.M., Pascual A., Rovito C., Galatte A., Scarafi a F., Sued O., Gutierrez O., Jolly S.S., Miró J.M., Eikelboom J., Loeb M., Maggioni A.P., Bhatt D.L., Yusuf S.; ECLA PHRI COLCOVID Trial Investigato. Eff ect of Colchicine vs Usual Care Alone on Intubation and 28-Day Mortality in Patients Hospitalized With COVID-19: A Randomized Clinical Trial. JAMA Netw Open. 2021;4(12):e2141328. DOI: 10.1001/jamanetworkopen.2021.41328
38. Alekberova Z.S., Nasonov E.L. Prospects for using colchicine in medicine: new evidence. Rheumatology Science and Practice. 2020;58(2):183–90 (In Russian). DOI: 10.14412/1995-4484-2020-183-190
39. Imazio M., Andreis A., Piroli F., Lazaros G., Gattorno M., Lewinter M., Klein A.L., Brucato A. Anti-interleukin 1 agents for the treatment of recurrent pericarditis: a systematic review and meta-analysis. Heart. 2021:heartjnl-2020-318869. DOI: 10.1136/heart-jnl-2020-318869
40. Baskar S., Klein A.L., Zeft A. The Use of IL-1 Receptor Antagonist (Anakinra) in Idiopathic Recurrent Pericarditis: A Narrative Review. Cardiol. Res. Pract. 2016;2016:7840724. DOI: 10.1155/2016/7840724
41. Nasonov E.L. The role of interleukin 1 in the development of human diseases. Rheumatology Science and Practice. 2018;56(4):19–27. (In Russian). DOI: 10.14412/1995-4484-2018-19-27
42. Dinarello CA. The IL-1 family of cytokines and receptors in rheumatic diseases. Na.t Rev. Rheumatol. 2019;15(10):612–32. DOI: 10.1038/s41584-019-0277-8
43. Chiabrando J.G., Bonaventura A., Vecchié A., Wohlford G.F., Mauro A.G., Jordan J.H., Grizzard J.D., Montecucco F., Berrocal D.H., Brucato A., Imazio M., Abbate A. Management of Acute and Recurrent Pericarditis: JACC State-of-the-Art Review. J. Am. Coll. Cardiol. 2020;75:76. DOI: 10.1016/j.jacc.2019.11.021
44. Nasonov E.L., Samsonov M.Yu. The role of interleukin 1 in the development of human diseases: focus on Anakinra (IL-1 receptor antagonist). Rheumatology Science and Practice. 2022;60(3):280–298. (In Russian). DOI: 10.47360/1995-4484-2022-280-298
45. Pereda C.A., Nishishinya-Aquino M.B., Brito-Garcia N., Del Campo D., Fontecha P., Rua-Figueroa I. Is cotrimoxazole prophylaxis against Pneumocystis jirovecii pneumonia needed in patients with systemic autoimmune rheumatic diseases requiring immunosuppressive therapies? Rheumatol. Int. 2021;41(8):1419–27. DOI: 10.1007/s00296-021-04808-4
46. Roque Rojas F., Mellor Pita S., Tutor de Ureta P. Idiopathic relapsing acute pericarditis: Report of one case with favorable response to anakinra. Med. Clin. (Barc). 2018;150:160. DOI: 10.1016/j.medcli.2017.08.005
47. Imazio M., Andreis A., De Ferrari G.M., Cremer P.C., Mardigyan V., Maestroni S., Luis S.A., Lopalco G., Emmi G., Lotan D., Marcolongo R., Lazaros G., De Biasio M., Cantarini L., Dagna L., Cercek A.C., Pivetta E., Varma B., Berkson L., Tombetti E., Iannone F., Prisco D., Caforio A.L.P., Vassilopoulos D., Tousoulis D., De Luca G., Giustetto C., Rinaldi M., Oh J.K., Klein A.L. Anakinra for corticosteroid-dependent and colchicine-resistant pericarditis: The IRAP (International Registry of Anakinra for Pericarditis) study. Eur. J. Prev. Cardiol. 2020;27(9):956–964. DOI: 10.1177/2047487319879534
48. Brucato A., Imazio M., Gattorno M., Lazaros G., Maestroni S., Carraro M., Finetti M., Cumetti D., Carobbio A., Ruperto N., Marcolongo R., Lorini M., Rimini A., Valenti A., Erre G.L., Sormani M.P., Belli R., Gaita F., Martini A. Eff ect of Anakinra on Recurrent Pericarditis Among Patients With Colchicine Resistance and Corticosteroid Dependence: The AIRTRIP Randomized Clinical Trial. JAMA. 2016;316(18):1906–1912. DOI: 10.1001/jama.2016.15826
49. Shaukat M.H., Singh S., Davis K., Torosoff M., Peredo-Wende R. Effi - cacy of anakinra for idiopathic and non-idiopathic pericarditis refractory or intolerant to conventional therapy. Eur. Heart J. Acute Cardiovasc. Care. 2020;9(8):888–892. DOI: 10.1177/2048872619886309
50. Theodoropoulou K., vS-G A., BressieuxDegueldre S., Prsa M., Angelini F., Boulos T., Hofer M. A case of corticosteroid-dependent recurrent pericarditis with diff erent response to two IL-1 blocking agents. Pediatr. Rheumatol. Online J. 2015;13(1):P1. DOI: 10.1007/s11886-020-01308-y
51. Kougkas N., Fanouriakis A., Papalopoulos I., Bertsias G., Avgoustidis N., Repa A., Sidiropoulos P. Canakinumab for recurrent rheumatic disease associated-pericarditis: a case series with long-term follow-up. Rheumatology (Oxford). 2018;57(8):1494–1495. DOI: 10.1093/rheumatology/key077
52. Signa S., D'Alessandro M., Consolini R., Miniaci A., Bustaff a M., Longo C., Tosca M.A., Bizzi M., Caorsi R., Mendonça L.O., Pession A., Ravelli A., Gattorno M. Failure of anti Interleukin-1β monoclonal antibody in the treatment of recurrent pericarditis in two children. Pediatr. Rheumatol. Online J. 2020;18(1):51. DOI: 10.1186/s12969-020-00438-5
53. Epcacan S., Sahin S., Kasapcopur O. Anaphylactic reaction to anakinra in a child with steroid-dependent idiopathic recurrent pericardi tis and successful management with canakinumab. Cardiol. Young. 2019;29:549–551. DOI: 10.1017/S1047951119000672
54. Klein A.L., Imazio M., Cremer P., Brucato A., Abbate A., Fang F., Insalaco A., LeWinter M., Lewis B.S., Lin D., Luis S.A., Nicholls S.J., Pano A., Wheeler A., Paolini J.F.; RHAPSODY Investigators. Phase 3 Trial of Interleukin-1 Trap Rilonacept in Recurrent Pericarditis.. N. Engl. J. Med. 2021;384(1):31–41. DOI: 10.1056/NEJMoa2027892
55. Vassilopoulos D., Lazaros G., Tsioufi s C., Vasileiou P., Stefana dis C., Pectasides D. Successful treatment of adult patients with idiopa-thic recurrent pericarditis with an interleukin-1 receptor antagonist (anakinra). Int. J. Cardiol. 2012;160(1):66–8. DOI: 10.1016/j.ijcard.2012.05.086
56. Jain S., Thongprayoon C., Espinosa R.E., Hayes S.N., Klarich K.W., Cooper L.T., Moder K.G., Anavekar N.S., Oh J.K., Matteson E.L. Eff ectiveness and Safety of Anakinra for Management of Refractory Pericarditis. Am. J. Cardiol. 2015;116(8):1277–9. DOI: 10.1016/j.amjcard.2015.07.047
57. Scott I.C., Hajela V., Hawkins P.N., Lachmann, H.J. A case series and systematic literature review of anakinra and immunosuppression in idiopathic recurrent pericarditis. J. Cardiol. Cases. 2011;12;4(2):e93–e97. DOI: 10.1016/j.jccase.2011.07.003
58. Rodriguez-Gonzalez M., Ruiz-Gonzalez E., Castellano-Martinez A. Anakinra as rescue therapy for steroid-dependent idiopathic recurrent pericarditis in children: case report and literature review. Cardiol. Young. 2019;29(2):241–243. DOI: 10.1017/S1047951118002020
59. Brucato A., Emmi G., Cantarini L., Di Lenarda A., Gattorno M., Lo palco G., Marcolongo R., Imazio M., Martini A., Prisco D. Mana gement of idiopathic recurrent pericarditis in adults and in children: a role for IL-1 receptor antagonism. Intern. Emerg. Med. 2018;13(4):475–489. DOI: 10.1007/s11739-018-1842-x
60. Finetti M., Insalaco A., Cantarini L., Meini A., Breda L., Alessio M., D'Alessandro M., Picco P., Martini A., Gattorno M. Long-term ef- fi cacy of interleukin-1 receptor antagonist (anakinra) in corticosteroid-dependent and colchicine-resistant recurrent pericarditis. J. Pediatr. 2014;164(6):1425–31.e1. DOI: 10.1016/j.jpeds.2014.01.065
61. Picco P., Brisca G., Traverso F., Loy A., Gattorno M., Martini A. Successful treatment of idiopathic recurrent pericarditis in children with interleukin-1beta receptor antagonist (anakinra): an unrecognized autoinfl ammatory disease? Arthritis Rheum. 2009;60(1):264–8. DOI: 10.1002/art.24174
62. Lazaros G., Imazio M., Brucato A., Vassilopoulos D., Vasileiou P., Gattorno M., Tousoulis D., Martini A. Anakinra: an emerging option for refractory idiopathic recurrent pericarditis: a systematic review of published evidence. J. Cardiovasc. Med. (Hagerstown). 2016;17(4):256–62. DOI: 10.2459/JCM.0000000000000266
63. Scardapane A., Brucato A., Chiarelli F., Breda L. Effi cacy of an interleukin-1b receptor antagonist (Anakinra) in idiopathic recurrent pericarditis. Pediatr. Cardiol. 2013;34:1989–1991. DOI: 10.1007/s00246-012-0532-0
64. Camacho-Lovillo M., Me´ndez-Santos A. Successful treatment of idiopathic recurrent pericarditis with interleukin-1 receptor antagonist (Anakinra). Pediatr. Cardiol 2013;34:1293–1294. DOI: 10.1007/s00246-013-0663-y
65. Wohlford G.F., Buckley L.F., Vecchié A., Kadariya D., Markley R., Trankle C.R., Chiabrando J.G., de Chazal H.M., Van Tassell B., Abbate A. Acute efects of interleukin-1 blockade using anakinra in patients with acute pericarditis. J. Cardiovasc. Pharmacol. 2020;76(1):50–52. DOI: 10.1097/FJC.0000000000000847
66. Peet C.J., Rowczenio D., Omoyinmi E., Papadopoulou C., Mapalo B.R.R., Wood M.R., Capon F., Lachmann H.J. Pericarditis and Autoinfl ammation: A Clinical and Genetic Analysis of Patients With Idiopathic Recurrent Pericarditis and Monogenic Autoinfl ammatory Diseases at a National Referral Center. J. Am. Heart Assoc. 2022;11(11):e024931. DOI: 10.1161/JAHA.121.024931
67. Tufan A., Avanoğlu Güler A., Matucci-Cerinic M. COVID-19, immune system response, hyperinfl ammation and repurposing antirheumatic drugs. Turk. J. Med. Sci. 2020;50(SI-1):620–632. DOI: 10.3906/sag-2004-168
68. Nasonov E.L. 2019 Coronavirus disease (COVID-19): contribution of rheumatology. Terapevticheskii arkhiv. 2021;93(5):537–550. (In Russian). DOI: 10.26442/00403660.2021.05.200799
69. Karaderi T., Bareke H., Kunter I., Seytanoglu A., Cagnan I., Balci D., Barin B., Hocaoglu M.B., Rahmioglu N., Asilmaz E., Taneri B. Host genetics at the intersection of autoimmunity and COVID-19: a potential key for heterogeneous COVID-19 Severity. Front Immunol. 2020;11:586111. DOI: 10.3389/fimmu.2020.586111
70. Bhadelia N., Belkina A.C., Olson A., Winters T., Urick P., Lin N., Rifkin I., Kataria Y., Yuen R.R., Sagar M., Snyder-Cappione J.E. Distinct autoimmune antibody signatures between hospitalized acute COVID-19 patients, SARS-CoV-2 convalescent individuals, and unexposed pre-pandemic controls. MedRxiv. 2021. DOI: 10.1101/2021.01.21.21249176.
71. Kyriazopoulou E., Huet T., Cavalli G., Gori A., Kyprianou M., Pickkers P., Eugen-Olsen J., Clerici M., Veas F., Chatellier G., Kaplanski G., Netea M.G., Pontali E., Gattorno M., Cauchois R., Kooistra E., Kox M., Bandera A., Beaussier H., Mangioni D., Dagna L., van der Meer J.W.M., Giamarellos-Bourboulis E.J., Hayem G.; International Collaborative Group for Anakinra in COVID-19. Eff ect of anakinra on mortality in patients with COVID-19: a systematic review and patient-level meta-analysis. Lancet Rheumatol. 2021;3(10):e690–e697. DOI: 10.1016/S2665-9913(21)00216-2
72. CORIMUNO-19 Collaborative group. Eff ect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial. Lancet Respir. Med. 2021;9(3):295–304. DOI: 10.1016/S2213-2600(20)30556-7
73. Karakike E., Dalekos G.N., Koutsodimitropoulos I., Saridaki M., Pourzitaki C., Papathanakos G., Kotsaki A., Chalvatzis S., Dimakopoulou V., Vechlidis N., Paramythiotou E., Avgoustou C., Ioakeimi dou A., Kouriannidi E., Komnos A., Neou E., Rovina N., Stefanatou E., Milionis H., Nikolaidis G., Koutsoukou A., Da moraki G., Dimopoulos G., Zoumpos V., Eugen-Olsen J., Akinosoglou K., Gatselis N.K., Koulouras V., Gkeka E., Markou N., Netea M.G., Giamarellos-Bourboulis E.J. ESCAPE: An Open-Label Trial of Personalized Immunotherapy in Critically lll COVID-19 Patients. J. Innate Immun. 2022;14(3):218–228. DOI: 10.1159/000519090
74. Henderson L.A., Canna S.W., Friedman K.G., Gorelik M., Lapidus S.K., Bassiri H., Behrens E.M., Ferris A., Kernan K.F., Schulert G.S., Seo P., Son M.B.F., Tremoulet A.H., Yeung R .S .M., Mudano A.S., Turner A.S., Karp D.R., Mehta J.J. American College of Rheumatology Clinical Guidance for Multisystem Infl ammatory Syndrome in Children Associated With SARS-CoV-2 and Hyperin-flammation in Pediatric COVID-19: Version 2. Arthritis Rheumatol. 2021;73(4):e13–e29. DOI: 10.1002/art.41616
75. Sukmarova Z.N., Simonenko V.B., Ibragimova F.M., Demyanenko A.V. Pericardial eff usion as a new specifi с c symptom of SARS-CoV-2. Clinical Medicine (Russian Journal). 2021;99(3):192–197. (In Russian). DOI: 10.30629/0023-2149-2021-99-3-192-197
76. Ferreira A.C., Soares V.C., de Azevedo-Quintanilha I.G., Dias S.D.S.G., Fintelman-Rodrigues N., Sacramento C.Q., Mattos M., de Freitas C.S., Temerozo J.R., Teixeira L., Damaceno Hottz E., Barreto E.A., Pão C.R.R., Palhinha L., Miranda M., Bou-Habib D.C., Bozza F.A., Bozza P.T., Souza TML. SARS-CoV-2 engages infl ammasome and pyroptosis in human primary monocytes. Cell Death Discov. 2021;7(1):43. DOI: 10.1038/s41420-021-00428-w
77. Karadeniz H., Yamak B.A., Özger H.S., Sezenöz B., Tufan A., Emmi G. Anakinra for the treatment of COVID-19-associated pericarditis: a case report. Cardiovasc. Drugs Ther. 2020;34:883–5. DOI: 10.1007/s10557-020-07044-3
78. Tschope C., Müller I., Xia Y., Savvatis K., Pappritz K., Pinkert S., Lassner D., Heimesaat M.M., Spillmann F., Miteva K., Bereswill S., Schultheiss H.P., Fechner H., Pieske B., Kühl U., Van Linthout S. NOD2 (Nucleotide-Binding Oligomerization Domain 2) Is a Major Pathogenic Mediator of Coxsackievirus B3-Induced Myocarditis. Circ. Heart Fail. 2017;10(9):e003870. DOI: 10.1161/CIRCHEART-FAILURE.117.003870
79. Kraft L., Erdenesukh T., Sauter M., Tschope C., Klingel K. Blocking the IL-1β signalling pathway prevents chronic viral myocarditis and cardiac remodeling. Basic Res. Cardiol. 2019;114(2):11. DOI: 10.1007/s00395-019-0719-0
80. Bonaventura A., Vecchie´ A., Mauro A.G., Brucato A.L., Imazio M., Abbate A. An update on the pathophysiology of acute and recurrent pericarditis. Panminerva Med 2020. DOI: 10.23736/S0031-0808.20.04205-6
81. Peiff er-Smadja N., Domont F., Saadoun D., Cacoub P. Corticosteroids and immunosuppressive agents for idiopathic recurrent pericarditis. Autoimmun. Rev. 2019;18(6):621–626. DOI: 10.1016/j.autrev.2019.04.001
82. Vianello F., Cinetto F., Cavraro M., Battisti A., Castelli M., Imbergamo S., Marcolongo R. Azathioprine in isolated recurrent pericarditis: a single centre experience. Int. J. Cardiol. 2011;147(3):477–8. DOI: 10.1016/j.ijcard.2011.01.027
83. Lotan D., Wasserstrum Y., Fardman A., Kogan M., Adler Y. Usefulness of Novel Immunotherapeutic Strategies for Idiopathic Recurrent Pericarditis. The American Journal of Cardiology. 2016;117(5):861– 866. DOI: 10.1016/j.amjcard.2015.12.012
84. Rud R.S., Blagova O.V., Kogan E.A., Novosadov V.M., Zaitsev A.Yu., Sedov V.P., Zaydenov V.A., Kupriyanova A.G., Kadochnikova V.V., Donnikov A.E., Nedostup A.V. Comparative effi cacy and safety of mycophenolate mofetil and azathioprine in combination with corticosteroids in the treatment of lymphocytic myocarditis. Russian Journal of Cardiology. 2021;26(11):4650. (In Russian). DOI: 10.15829/1560-4071-2021-4650
85. Narasimhan B., Turagam M.K., Garg J., Della Rocca D.G., Gopinathannair R., Biase L.D., Romero J., Mohanty S., Natale A., Lakkireddy D. Role of immunosuppressive therapy in the management refractory postprocedural pericarditis. J. Cardiovasc. Electrophysiol. 2021;32(8):2165–2170. DOI: 10.1111/jce.15069
86. Combe B., Didry C., Gutierrez M., Anaya J.M., Sany J. Accelerated nodulosis and systemic manifestations during methotrexate therapy for rheumatoid arthritis. Eur. J. Med. 1993;2(3):153–6. PMID: 8261056
87. Peiff er-Smadja N., Domont F., Saadoun D., Cacoub P. Corticosteroids and immunosuppressive agents for idiopathic recurrent pericarditis. Autoimmun. Rev. 2019;18(6):621–626. DOI: 10.1016/j.autrev.2019.04.001
88. Lazaros G., Antonopoulos A.S., Antonatou K., Skendros P., Ritis K., Hadziyannis E., Lazarou E., Leontsinis I., Simantiris S., Vlachopoulos C., Tousoulis D., Vassilopoulos D. Hydroxychloroquine for colchicine-resistant glucocorticoid-dependent idiopathic recurrent pericarditis: a pilot observational prospective study. Int. J. Cardiol. 2020;311:77–82. DOI: 10.1016/j.ijcard.2020.03.069
89. Imazio M., Lazaros G., Picardi E., Vasileiou .P, Carraro M., Tousoulis D., Belli R., Gaita F. Intravenous human immunoglobulins for refractory recurrent pericarditis. J. Cardiovasc. Med. 2016;17(4):263–9. DOI: 10.2459/JCM.0000000000000260
90. Moretti M., Buiatti A., Merlo M., Massa L., Fabris E., Pinamonti B., Sinagra G. Usefulness of high-dose intravenous human immunoglobulins treatment for refractory recurrent pericarditis. Am. J. Cardiol. 2013;112(9):1493–8. DOI: 10.1016/j.amjcard.2013.06.036
91.
Review
For citations:
Sukmarova Z.N., Simonenko V.B., Nasonov E.L. Therapy of pericarditis with colchicine, interleukin-1 antagonists, immunosuppressants. Clinical Medicine (Russian Journal). 2023;101(1):6-17. (In Russ.) https://doi.org/10.30629/0023-2149-2023-101-1-6-17
Views:
894
Email this article 